TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke

Completed

Phase N/A Results N/A

Trial Description

Single-center, prospective, descriptive and biomedical research with controls, without health product.
Depression is the second risk factor for stroke as tobacco smoking following hypertension. Peripheral abnormalities in serotonin parameters were described in depression and tobacco smoking. The investigators hypothesized dysregulations in pathways of serotonin (5-HT), which has notably complex vasomotor effects and of kynurenine which could have cognitive dysfunction effects.
The aim of this study is to evaluate simultaneously the involvement of serotonin and kynurenine pathways parameters in patients suffering from a cerebral infarction shortly after the onset (less than 4 hours and a half), within a 2 days follow-up (Day 1 and Day 2) and 3 months after the cerebral infarction.

Detailed Description

Tryptophan (TRP), an essential aminoacid, is metabolized in the serotonin (5-HT) or in the kynurenine (KYN) pathway. Serotonin is catabolized to 5-HIAA (5-hydroxyindole amino acid) by monoamine oxidase A (MAOA). The TRP to KYN transformation is regulated by indoleamine 2,3-dioxygenase (IDO).
The primary objective was the measurements of serotonin and kynurenine pathways parameters which were performed in blood and urine samples using different HPLC techniques and of serotonin transporters and receptors which were determined in blood platelets. The results in patients were compared to those measured in controls matched for age, gender, tobacco consumption and season of inclusion.
The secondary objective was to evaluate the potential relationships between these 5-HT and Kyn pathways biomarkers concentrations, MAOA and IDO enzymatic activations and clinical outcome and criteria.

Conditions

Interventions

  • Usual care patients in neurology department Other
    Intervention Desc: patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
    ARM 1: Kind: Experimental
    Label: Patients presenting cerebral infarction
    Description: no intervention of health product administration,
  • Blood and urines sampling Biological
    Intervention Desc: Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
    ARM 1: Kind: Experimental
    Label: Patients presenting cerebral infarction
    Description: no intervention of health product administration,
    ARM 2: Kind: Experimental
    Label: Historical controls
    Description: no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
  • Psychiatric evaluation Procedure
    Intervention Desc: depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
    ARM 1: Kind: Experimental
    Label: Patients presenting cerebral infarction
    Description: no intervention of health product administration,

Outcomes

Type Measure Time Frame Safety Issue
Primary Measure of serotonin pathway parameters concentrations in blood and urine samples Day 1
Primary Measure of serotonin pathway parameters in blood samples Day 1
Primary Measure of serotonin pathway parameters in blood and urine samples Day 2
Primary Measure of kynurenin pathway parameters in blood samples Day 1

Sponsors